Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) Chief Accounting Officer, Emily Pimblett, has recently sold a portion of her company stock, according to a new SEC filing.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
•
•
•
•
•
•
•
•
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Finnhub
40%
investing.com
20%
SeekingAlpha
20%
Others
20%
Country
US
Industry
Health Care
Market Cap
Micro Cap
Num. Employees
30
IPO Date
Aug 10, 2021
Country
US
Industry
Health Care
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Redmond, Washington and currently employs 30 full-time employees. The company went IPO on 2021-08-10. The company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with therapeutic potential to deliver improved therapeutics for patients with these disorders. Its lead program is ETX-123, a Kv7.2/3 potassium channel opener. Kv7.2/3 has been clinically validated as a therapeutic target for both epilepsy and pain, with further encouraging clinical data in depression. Its ETX-123 lead candidate is an generate new chemical entities designed to harness the efficacy of the Kv7.2/3 channel mechanism while attempting to improve the safety and tolerability relative to earlier molecules, based on its insights into the mechanisms of toxicity and the potency and selectivity profile.
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Low Data
Related Stocks
Related Stocks
Stocks being mentioned with ELYM